



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI et al.

Serial No.: 10/075,823

Examiner:


Date Filed: February 12, 2002

Group:

For: VEGF-D EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on October 31, 2002.

  
Reg. No. 42,730  
Stanley A. Kim, Ph.D., Esq.

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, DC 20231

RECEIVED

NOV 08 2002

Dear Sir:

TECH CENTER 1600/2900

Please find enclosed for filing the following:

- X Information Disclosure Statement, with PTO-1449, and references; and
- X 1 postcard.


Although no fee is believed due, please charge any underpayment to Deposit Account No.

50-0951. This letter is submitted in duplicate.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: October 31, 2002

  
Stanley A. Kim, Ph.D., Esq.  
Registration No. 42,730  
222 Lakeview Avenue, Suite 400  
P.O. Box 3188  
West Palm Beach, FL 33402-3188  
Tel: 561-653-5000

Docket No. 6460-41



THH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI et al.

Serial No.: 10/075,823

Examiner:


Date Filed: February 12, 2002

Group:

For: VEGF-D EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on October 31, 2002

  
Stanley A. Kim, Ph.D., Esq.

Reg. No. 42,730

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner for Patents  
Washington, DC 20231

NOV 08 2002

TECH CENTER 1600/2900

Dear Sir:


Pursuant to the Duty to Disclose under 37 CFR 1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.


The claimed invention is believed patentable over the disclosures enclosed. This citation is intended to give the Examiner an opportunity to make an independent evaluation. No representations are made regarding these materials.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: October 31, 2002

  
Stanley A. Kim, Ph.D., Esq.  
Registration No. 42,730  
222 Lakeview Avenue, Suite 400  
P.O. Box 3188  
West Palm Beach, FL 33402-3188  
Tel: 561-653-5000



Sheet 1 of 1

Form PTO-101  
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
**6460-41**APPLICATION NO.  
**10/075,823**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
**Debinski et al.**FILING DATE  
**February 12, 2002**

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Debinski et al., "VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme," Molecular Medicine, 7: 598-608, 2001
		Title et al., "Vascular Endothelial Growth factor (VEGF) Receptor-2 Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro," Journal Pharmacol. & Exp. Therapeutics, 299: 1073-1085, 2001

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900